Codice QR

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland

ObjectiveBoth camrelizumab plus paclitaxel and carboplatin (CTC) and sintilimab plus gemcitabine and cisplatin or carboplatin (SGP) have been approved by the National Medical Products Administration of China (NMPA) for the first-line treatment of local advanced or metastatic sqNSCLC. However, the co...

Descrizione completa

Salvato in:
Autori principali: Xiaoting Liu, Xiao-xue Liu, Wenqing Shao, Yi Zhou, Jing Zhang, Cuirong Zhao, Chengwu Shen
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2024-07-01
Serie:Frontiers in Pharmacology
Soggetti:
cost-effectiveness
squamous NSCLC
first-line treatment
camrelizumab
sintilimab
Accesso online:https://www.frontiersin.org/articles/10.3389/fphar.2024.1356725/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi